IPO
-
-
-
-
-
-
-
Nkarta Announces Presentation of Preclinical Data on NKX019, Engineered NK Cell Therapy Candidate Targeting CD19, at the Annual Meeting of the Society for Immunotherapy of Cancer
-
-
-
-
-
-
-
Nkarta, Inc. (NKTA) Prices 14M Share IPO at $18/Sh
-
-
118,853 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

